Literature DB >> 9742053

Familial hypertrophic cardiomyopathy: from mutations to functional defects.

G Bonne1, L Carrier, P Richard, B Hainque, K Schwartz.   

Abstract

Hypertrophic cardiomyopathy is characterized by left and/or right ventricular hypertrophy, which is usually asymmetric and involves the interventricular septum. Typical morphological changes include myocyte hypertrophy and disarray surrounding the areas of increased loose connective tissue. Arrhythmias and premature sudden deaths are common. Hypertrophic cardiomyopathy is familial in the majority of cases and is transmitted as an autosomal-dominant trait. The results of molecular genetics studies have shown that familial hypertrophic cardiomyopathy is a disease of the sarcomere involving mutations in 7 different genes encoding proteins of the myofibrillar apparatus: ss-myosin heavy chain, ventricular myosin essential light chain, ventricular myosin regulatory light chain, cardiac troponin T, cardiac troponin I, alpha-tropomyosin, and cardiac myosin binding protein C. In addition to this locus heterogeneity, there is a wide allelic heterogeneity, since numerous mutations have been found in all these genes. The recent development of animal models and of in vitro analyses have allowed a better understanding of the pathophysiological mechanisms associated with familial hypertrophic cardiomyopathy. One can thus tentatively draw the following cascade of events: The mutation leads to a poison polypeptide that would be incorporated into the sarcomere. This would alter the sarcomeric function that would result (1) in an altered cardiac function and then (2) in the alteration of the sarcomeric and myocyte structure. Some mutations induce functional impairment and support the pathogenesis hypothesis of a "hypocontractile" state followed by compensatory hypertrophy. Other mutations induce cardiac hyperfunction and determine a "hypercontractile" state that would directly induce cardiac hypertrophy. The development of other animal models and of other mechanistic studies linking the genetic mutation to functional defects are now key issues in understanding how alterations in the basic contractile unit of the cardiomyocyte alter the phenotype and the function of the heart.

Entities:  

Mesh:

Year:  1998        PMID: 9742053     DOI: 10.1161/01.res.83.6.580

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  77 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

Review 2.  The cardiomyopathies: an overview.

Authors:  M J Davies
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 3.  Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders.

Authors:  N Gregersen; P Bross; M M Jørgensen; T J Corydon; B S Andresen
Journal:  J Inherit Metab Dis       Date:  2000-07       Impact factor: 4.982

4.  Mutation of the myosin converter domain alters cross-bridge elasticity.

Authors:  Jan Köhler; Gerhard Winkler; Imke Schulte; Tim Scholz; William McKenna; Bernhard Brenner; Theresia Kraft
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

5.  Disease-causing mutations in cardiac troponin T: identification of a critical tropomyosin-binding region.

Authors:  T Palm; S Graboski; S E Hitchcock-DeGregori; N J Greenfield
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

Review 6.  The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders.

Authors:  N Gregersen; P Bross; B S Andrese; C B Pedersen; T J Corydon; L Bolund
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

7.  Complexity in simplicity: monogenic disorders and complex cardiomyopathies.

Authors:  J Chen; K R Chien
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

8.  Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies.

Authors:  Kenneth R Chien
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

9.  Roles of phosphorylation of myosin binding protein-C and troponin I in mouse cardiac muscle twitch dynamics.

Authors:  Carl W Tong; Robert D Gaffin; David C Zawieja; Mariappan Muthuchamy
Journal:  J Physiol       Date:  2004-06-11       Impact factor: 5.182

10.  The role of Akt/GSK-3beta signaling in familial hypertrophic cardiomyopathy.

Authors:  Stephen W Luckey; Lori A Walker; Tyson Smyth; Jason Mansoori; Antke Messmer-Kratzsch; Anthony Rosenzweig; Eric N Olson; Leslie A Leinwand
Journal:  J Mol Cell Cardiol       Date:  2009-02-21       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.